The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Open accessAbstract
Glycogen synthase kinase-3β (GSK-3β), a serine/threonine protein kinase, is a complex regulator of numerous cellular functions. GSK-3β is a unique kinase which is constitutively active in resting and nonstimulated cells. GSK-3β has been implicated in a wide range of diseases including neurodegeneration, inflammation and fibrosis, noninsulin-dependent diabetes mellitus, and cancer. It is a regulator of NF-κB–mediated survival of cancer cells, which provided a rationale for the development of GSK-3 inhibitors targeting malignant tumors. Recent studies, many of them reported over the past decade, have identified GSK-3β as a potential therapeutic target in more than 15 different types of cancer. Whereas only active GSK-3β is expressed in cancer cell nucleus, aberrant nuclear accumulation of GSK-3β has been identified as a hallmark of cancer cells in malignant tumors of different origin. This review focuses on the preclinical and clinical development of GSK-3 inhibitors and the potential therapeutic impact of targeting GSK-3β in human cancer. Clin Cancer Res; 23(8); 1891–7. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · cited 1×
“A subsequent ARGO doubleblind, randomized, placebo-controlled phase II trial in patients with Alzheimer disease enrolled 306 patients aged 50 to 85 years old with mild to moderate disease (53).”
MethodTreatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329 · cited 2×
“30% in the placebo group) that were not dose dependent (52).”
BackgroundGlycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
Wang, Z., Smith, K. S., Murphy, M., Piloto, O., Somervaille, T. C. P., & Cleary, M. L. (2008) · Nature · doi:10.1038/nature07284 · Cited by 265
GSK-3 inhibition sensitizes acute myeloid leukemia cells to 1,25D-mediated differentiation
Gupta, K., Stefan, T., Ignatz-Hoover, J., Moreton, S., Parizher, G., Saunthararajah, Y., & Wald, D. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2290 · Cited by 44
Si, J., Mueller, L., & Collins, S. J. (2011) · Leukemia · doi:10.1038/leu.2011.171 · Cited by 30
Cited by
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., et al. (2020) · Cells · doi:10.3390/cells9051110 · Cited by 284
GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer
Lin, J., Song, T., Li, C., & Mao, W. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118659 · Cited by 268
Zhong, W., Shahbaz, O., Teskey, G., Beever, A., Kachour, N., Venketaraman, V., & Darmani, N. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115797 · Cited by 253
Wnt signaling deregulation in the aging and Alzheimer’s brain
Palomer, E., Buechler, J., & Salinas, P. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00227 · Cited by 237
Chen, M., Li, J., Liang, J., Thompson, Z. S., Kathrein, K., Broude, E. V., & Roninson, I. B. (2019) · Cells · doi:10.3390/cells8111413 · Cited by 57
“The striking induction of intracellular vesicle formation by Cmpd3 could conceivably provide a cause of toxicity, whereas inhibition of GSK3B, an off-target of Cmpd4, has been associated with significant toxicities [28,29], including the induction of bone lesions [28] that appear to be similar to those observed by Cla…”
Result
Metadata
- Authors
- Walz, A., Ugolkov, A., Chandra, S., Kozikowski, A., Carneiro, B. A., O'Halloran, T. V., Giles, F. J., Billadeau, D. D., & Mazar, A. P.
- Venue
- Clinical Cancer Research
- Published
- 2017-04-13
- Volume
- 23
- Issue
- 8
- Pages
- 1891-1897
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2569558294
- Cited by
- 160
- References
- 7
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2240
- The paper
- Walz, A., Ugolkov, A., Chandra, S., Kozikowski, A., Carneiro, B. A., O'Halloran, T. V., Giles, F. J., Billadeau, D. D., & Mazar, A. P. (2017). Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.